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Abstract
Botulism is a severe and potentially lethal paralytic disease caused by several botulinum neurotoxin-producing
Clostridia spp. In China, the majority of the cases caused by botulism were from less-developed rural areas. Here,
we designed specific substrate peptides and reconfigured gold nanoparticle-based lateral flow test strip (LFTS) to
develop an endopeptidase-based lateral flow assay for the diagnosis of botulism. We performed this lateral flow
assay on botulinum neurotoxin-spiked human serum samples. The as-prepared LFTS had excellent performance in
the detection of botulinum neurotoxin using only 1 μL of simulated serum, and its sensitivity and specificity were
comparable to that of mouse lethality assay. Moreover, the assay takes only half a day and does not require highly
trained laboratory staff, specialized facility, or equipment. Finally, our LFTS can be potentially extended to other serotypes
of BoNTs by designing specific substrate peptides against the different types of BoNTs. Overall, we demonstrate a strategy
by which LFTS and endopeptidase activity assays can be integrated to achieve facile and economic diagnosis of botulism
in resource-limited settings.
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Background
The botulinum neurotoxins (BoNT) are produced by sev-
eral Clostridia spp. as single 150-kDa polypeptide chains,
which consist of a 100-kDa heavy chain joined by a disul-
fide bond to a 50-kDa light chain. Serotypically, this
deadly toxin includes seven distinct types from BoNT/A
to BoNT/G and possesses the metallopeptidase activity
specific for the soluble N-ethylmaleimide-sensitive factor
activating protein receptor (SNARE) complex. It could
block the neurotransmitter release of the intoxicated per-
ipheral neurons and cause death in consequence of block-
ade of respiratory function in vertebrates [1–4]. Among
the seven serotypes, BoNT/A and B are commonly associ-
ated with human botulism, but the former causes more
severe consequences than the latter [5].
Due to the severity of botulism, along with clinical man-
ifestion, early detection of BoNTs in patients is required
to deliver appropriate treatment. Currently, the detection
of BoNTs is mainly based on biological and immuno-
logical techniques following culturing of suspicious
strains. For decades, mouse lethality assay (MLA) has still
served as the “gold standard method” approved by the As-
sociation of Official Analytical Chemists (AOAC) for the
analysis of BoNTs, which is able to detect approximately
10 pg/mL of the toxin [6–9]. However, MLA is costly
(requirements of expensive animal facilities) and time
consuming (up to 4 days), and most important, it involves
in the ethical problems for the use of live animals [9, 10].
The most frequently used immunological method for
toxin detection and serotyping is sandwich-based enzyme-
linked immunosorbent assay (ELISA). Its ease of use, good
specificity, and high-throughput capabilities make it suit-
able for the application in routine laboratories [11]. Never-
theless, the major drawback is that it lacks capacity to
differentiate active BoNTs from the inactive toxins. More-
over, its application in resource-limited areas is restricted
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owing to the requirement for specialized microplate
reader and tedious procedure.
In this article, we developed a very easy gold
nanoparticle-based LFTS (lateral flow test strip) to de-
tect active BoNT/A in patients’ serum sample. It is well
known that BoNT/A selectively cleaves one of the three
SNARE polypeptides, SNAP-25 (25-kDa synaptosome
associated protein). Therefore, the zinc-dependent endo-
peptidase activity of BoNT/A was utilized to design a
specific substrate peptide with a His-tag at the carboxyl
terminal end and a biotin at the amino terminus (Fig. 1a).
The sequence of specific cleavage site was based on
SNAPtide®, a very short SNAP-25 homologue with a
unique cleavage site for BoNT/A [12, 13]. After incuba-
tion with BoNT/A-spiked serum sample for a certain
time duration, the biotin at the amino terminus of the
peptide was cleaved off, resulting in that gold
nanoparticle-labeled streptavidin-substrate peptide com-
plexes could not be captured on the test zone of LFTS,
thus, LFTS presented a different coloration from BoNT/
A-negative result (Fig. 1b).
Results
Purification and Characterization of BoNTs
Since the differences in purification methods or manu-
facturing processes may influence the activity of BoNTs,
there remains a paucity of appropriate and comparable
quantitative data of BoNTs analysis from variety of
methods based on its metallopeptidase activity [14, 15].
In order to provide an objective information for the
comparison between various analytic methods of BoNTs,
we quantified the as-prepared BoNTs by BCA protein
assay and determined its lethal toxicity by MLA. The re-
sults of SDS-PAGE showed that the purified BoNTs were
the complexes with hemagglutinin (HA) and non-toxic
non-HA (NTNH) (Fig. 2). After the treatment of dithio-
threitol (DTT), the interchain disulfide bond in both sero-
types could be reduced resulting in 100 kD heavy chain
and 50 kDa light chain (Fig. 2, lane 2 and 4). Because the
BoNT/B was the crude extract by DEAE-sepharose chro-
matography in this work, its purity was clearly below that
of BoNT/A (Fig. 2, lane 3 and 4). The results of BCA pro-
tein assay showed that the concentrations of the BoNT/A
and BoNT/B were 0.2 mg/mL and 11.3 mg/mL respect-
ively. The data of MLA indicated that the lethal toxicity
were 1.3 × 107 median lethal dose (LD50)/mL for BoNT/A
and 1 × 106 LD50/mL for BoNT/B (Table. 1).
The Optimization and Performance of LFTS
Theoretically, the intensity of the color depicted in test
lines was determined by the quantity of the substrate
peptide when the amount of gold nanoparticle conju-
gates is constant. However, the excess quantity of the
Fig. 1 The diagrammatic representation of the as-prepared LFTS. a The
sequence of specific substrate peptide and its cleavage site. b
The schematic principle of the LFTS based on the endopeptidase
activity of BoNT/A (The inset is the diagrammatic drawing of test results,
C: control line; T: test line; S: sample pad)
Fig. 2 The SDS–PAGE analysis of the purified BoNT/A and BoNT/B
complex. (Lane 1: BoNT/A; Lane 2: DTT-treated BoNT/A; Lane 3: BoNT/B;
Lane 4: DTT-treated BoNT/B)
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substrate peptide would inevitably result in prolongation of
the enzymolysis time thus reducing the sensitivity of the
assay within the given digestion time. Therefore, the sub-
strate peptide was diluted serially and applied into the
LFTS to determine the minimum quantity of substrate
peptide which could clearly generate a red visual signal in
test line. In this work, the minimum quantity of the sub-
strate peptide was found to be 0.2 ng/μL, but the intensity
of the color was visibly less clear than that of 1 ng/μL. As a
result, 1 ng/μL was adopted as the optimized concentration
of the substrate peptide for the subsequent test (Fig. 3).
Because the limit of detection (LOD) of MLA for the
purified BoNT/A was approximately 20 pg/mL, this
LOD was artificially taken as the goal that our LFTS
should achieve and used to explore the optimal digestion
time. According to the results, the LFTS generated
significant difference in colorization after 6 h of di-
gestion of the substrate peptide by 20 pg/mL BoNT/
A-spiked PBS solution and the red signal in test line
disappeared completely after 12 h of incubation (Fig. 4).
As a consequence, 12 h was determined as the optimal di-
gestion time in the later experiments.
SNAPtide is a synthetic, commercially available, 13-
amino acid peptide that contains the native SNAP-25
cleavage site for BoNT/A, the specifity of which has been
confirmed extensively [16–18]. Hence, we only used
BoNT/B-spiked and BoNT-negative sera to test the specif-
ity of the LFTS in this study. The results of these two sam-
ples showed that both LFTSs displayed visible test and
control lines, validating the proper specifity of the assay
(Fig. 5b and N strips). BoNT-negative sera were spiked
with purified BoNT/A to establish the LOD for the LFTS.
BoNT/A was serially diluted in sera from 2 to 0.2 pg/mL,
and the qualitative detection by visual inspection revealed
a significant decrease in test line density with an LOD of
20 pg/mL which was equivalent to 1.3 LD50/mL (Fig. 5
No. 1 ~5 strips). Besides, MLA was conducted with the
same BoNT/A-spike samples and the LOD were found to
be 20 pg/mL which is consistent with that of the LFTS.
Discussion
Botulism is a severe and potentially lethal paralytic dis-
ease characterized by symmetric cranial nerve palsy,
commonly followed by symmetric, descending, flaccid
paralysis of involuntary muscles, which may result in
Table 1 The lethal toxicity of BoNT/A and B calculated by Reed–
Muench method [29]




BoNT/A 1:5 × 106 3 1 3 1 75
1:1 × 107 0 4 0 5 0
1:2 × 107 0 4 0 9 0
BoNT/B 1:2 × 105 4 0 7 0 100
1:4 × 105 3 1 3 1 75
1:8 × 105 0 4 0 5 0
Fig. 3 The determination of the minimum quantity of the substrate
peptide. The concentrations of substrate peptide used in the
experiments were from 0 to 2 ng/μL (from right to left)
Fig. 4 The determination of the optimal digestion time of the LFTS.
The digestion time were from 0 to 12 h (from left to right)
Fig. 5 The specifity and sensitivity of the LFTS. (B: BoNT-negative
serum; N: BoNT/B-spiked serum; 1 ~ 5: 0.2, 2, 20, 200, and 2 ng/mL
BoNT/A-spiked sera respectively)
Liu et al. Nanoscale Research Letters  (2017) 12:227 Page 3 of 6
respiratory compromise and death [19]. The mortality
among the confirmed cases of botulism is reported to be
3–10% and that of untreated cases could reach up to 40%
or more [20–22]. The key to treat botulism lies in early
diagnosis, intensive supportive care, and timely botulinum
antitoxin administration. Particularly in suspected infant
botulism cases, the human-derived botulinum antitoxin
has been recommended to administer as early as possible
by some experts [19]. Moreover, unlike the medication for
common bacterial infections, antibiotics are not recom-
mended for infant botulism because antibiotic adminis-
tration may result in Clostridium botulinum lysis and
subsequent BoNTs release into the gut lumen [19, 23].
Therefore, reducing the time needed for clinical diagnosis
plays an absolutely vital role in the treatment for botulism.
As noted before, MLA is universally accepted for con-
firming BoNT by international regulatory agencies.
However, this method takes up to 4 days, or even longer
if toxin is to be serotyped. The other drawbacks include
the laborious operating procedure, expensive animal care
facilities, and health risks by conducting animal experi-
ments and ethical objections. In past decades, significant
progress has been made to develop alternative in vitro
detection methods such as immunoassays, endopeptid-
ase activity assays, mass spectrometry, cell-based assays,
and so on [24]. Many of them have achieved the sensitiv-
ities near or below that of MLA. It is worth mentioning
that most tests require highly trained laboratory staff, spe-
cialized equipment and material. Gold nanopartle-based
LFTS are self-contained without the need for sophisticated
equipment or an expert analyst [25]. Thus it is ideal for
field situations or resource-limited settings. Nevertheless,
based on current double-antibody sandwich format, the
sensitivity of LFTS is inferior to that of MLA.
Our LFTS assay combines the very best of LFTS and
endopeptidase activity assays. The former offers a famil-
iar and easy-to-use laboratory assay format. The latter
provides the specificity to BoNT/A and enzyme-based
signal amplification processes. Its sensitivity of 20 pg/mL
approaches that of MLA (10 pg/mL). Compared with
traditional MLA or ELISA methods, the assay takes only
half a day and consumes significantly less sample and re-
agents, which will significantly reduce assay cost and
simplify disposal. In China, the majority of the cases
caused by botulism were from less-developed rural areas
[26]. This assay may contribute to the improvement of
treatment for botulism without any requirements for
skilled laboratory staff, additional facilities, or equip-
ments. Finally, our LFTS can be potentially extended to
other serotypes of BoNTs by designing specific substrate
peptides. Overall, we demonstrate a strategy by which
LFTS and endopeptidase activity assays can be inte-
grated to achieve on-site diagnosis of botulism in
resource-limited settings.
Conclusions
In this work, we designed specific substrate peptides and
reconfigured gold nanoparticle-based lateral flow test
strip (LFTS) to develop an endopeptidase-based lateral
flow assay for the diagnosis of botulism. The LFTS con-
sumes only 1 μL of serum sample and had excellent sen-
sitivity and specificity which were comparable to those
of mouse lethality assay. Moreover, the assay takes only
half a day and does not require highly trained laboratory
staff, specialized facility, or equipment. Finally, our LFTS
can be potentially extended to other serotypes of BoNTs
by designing specific substrate peptides against the dif-
ferent types of BoNTs. All in all, we demonstrate a strat-
egy by which LFTS and endopeptidase activity assays
can be integrated to achieve facile and economic diagno-
sis of botulism in resource-limited settings.
Methods
Materials
Gold-in-a-Box™ conjugation kit (20 nm, 15 OD gold
nanoparticle) was purchased from BioAssay Works, LLC
(Ijamsville, MD, USA). HiPrep DEAE FF 16/10 and
HiPrep 16/60 Sephacryl S-200 HR were from GE
Healthcare Bio-Sciences AB (Uppsala, Sweden). C. botu-
linum type A strain 62A and C. botulinum type B strain
621 were obtained from the bacterial culture collection
of Beijing Institute of Microbiology and Epidemiology.
Streptavidin, and anti-Streptavidin antibodies were
bought from ProSpec-Tany TechnoGene Ltd (Ness
Ziona, Israel), and anti-His monoclonal antibodies was
bought from Abbkine Inc (Redlands, CA, USA). Pierce®
BCA Protein Assay Kit was purchased from Thermo
Fisher Scientific Inc (Waltham, MA, USA). The sub-
strate peptide with a His-tag at the carboxyl terminal
end and a biotin at the amino terminus was synthesized
by GL Biochem (Shanghai) Ltd (Shanghai, China). High-
flow nitrocellulose membranes, glass fiber, and absorption
pad were supplied by Millipore (Billerica, MA, USA). All
preparations and measurements were carried out in deion-
ized water as solvent with 18 MΩ/cm or less. All other
reagents were purchased domestically. BoNT/A and B-
negative sera were obtained from volunteer blood donors.
Specific pathogen-free (SPF) female BALB/c mice were
purchased from Beijing Vital River Laboratory Animal
Technology Co. Ltd, Beijing, China. All animal experi-
ments used in this study were performed according to the
protocols approved by the Institutional Animal Care and
Use Committee of Beijing Institute of Microbiology and
Epidemiology (Identification code for mice: IACUC of
AMMS-12-2015-012; Date of approval: 9 December 2015).
Purification of BoNTs
The C. botulinum type A strain was cultured in TPYG
medium (3% bacto peptone, 0.5% glucose, 0.5% yeast
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extract and 0.05% L-cysteine HCl, 0.025% Na-
thioglycolic acid,pH 7.5,) for 20 h at 37 °C, then trans-
ferred to TPOM (yeast extract 1%, casein hydrolysate
2%, Na-thioglycolic acid 0.05%, L-cysteine HCl 0.1% and
glucose 0.5% pH 7.2–7.4) at the ratio of 1:100 and cul-
tured for 4 days at the same temperature. After the
toxins were released from the cytosol following bacterial
autolysis, 3 N H2SO4 was dropped into the medium
until its pH value reached 3.4. The medium was kept at
4 °C overnight and then centrifuged at 12,000 × g for
30 min. The supernatant was discarded, and the precipi-
tates were dissolved with 0.2 M PBS (pH 6.0) under stir-
ring for 1 h. The solution was centrifuged at 12,000 × g
for 30 min. Ribonuclease was added into the super-
natant at a final concentration of 100 μg/mL and
incubated at 34 °C for 3 h. Thereafter, the crude
BoNT/A were precipitated with 60% ammonium
sulfate at 4 °C overnight. After centrifugation at
10,000 × g for 30 min, the precipitates are dissolved in
0.05 M citric acid buffer (pH 5.5). After another cen-
trifugation at 10,000 × g for 30 min, BoNT/A in the
supernatant was purified by DEAE-Sepharose and
Sephacryl-200 column successively. The purification of
BoNT/B was completed according to the previous
methods published by our laboratory without polyethylene
glycol (PEG) precipitation and Sephacryl-200 column
process [27]. BCA (bicinchoninic acid) protein assay and
SDS-PAGE were used to analyze the two toxins.
Lethal Toxicity of the As-Prepared BoNTs
The lethal toxicity of the as-prepared BoNTs was deter-
mined according to the previous method [28]. Briefly,
the BoNTs were diluted twofold serially in 0.02%
gelatin-0.05 M acetate buffer, pH 6.0 from 5 × 106 to 2 ×
107 for BoNT/A and from 2 × 105 to 8 × 105 for BoNT/
B. Four mice were injected with 0.5 mL doses of each di-
lution peritoneally and observed for 4 days. The LD50
was calculated by the Reed–Muench method [29].
Preparation of Lateral Flow Test Strips
The anti-His monoclonal antibodies and the anti-
streptavidin antibody were dispensed on the nitrocellulose
membrane with Biodot XYZ3000 dispenser at concentra-
tion of 1 mg/mL as test line and control line respectively.
The nitrocellulose membrane was then dried for 30 min.
The colloidal gold conjugates were prepared according to
the producer’s instruction and printed on conjugate pad at
the proportion of 4 uL per test strip and dried at room
temperature. Absorbent pad, nitrocellulose membrane,
conjugate pad, and sample pad were pasted on the lamin-
ating card in order with proper overlapping distance.
Eventually, the whole card was cut into final test strips of
4 mm in width with guillotine cutter.
Optimization of Detection Conditions
The substrate peptide was first dissolved in 0.01 M PBST
containing 0.5 mM ZnCl2 (pH 6.0, 0.05% Tween-20) at
the concentration of 0.1, 0.2, 0.5, 1, and 2 ng/μL. One
microliter of substrate peptides mentioned above were
blended with 100 μL PBST respectively and then added
into the sample pad of LFTS. Five minutes later, the color-
ization on test zone was used to determine the minimum
quantity of the substrate peptide used in digestion step. In
addition, 1 μL BoNT/A (20 pg/mL) and 1 μL substrate
peptide solution were mixed thoroughly in 18 μL 0.01 M
PBST containing 0.5 mM ZnCl2 and incubated at 37 °C
for 0, 2, 4, 6, 8, 10, and 12 h respectively. The substrate
peptide solution digested for different durations was then
blended with 100 μL PBST and added into the sample pad
of LFTS. Five minutes later, the colorization on test zone
was used to determine the minimum digestion time.
Detection of BoNT/A-Spiked Samples
Firstly, the collected BoNT-negative sera were kept in
room temperature for 10 min before use. Then, the puri-
fied BoNT/A was spiked in the sera at the concentra-
tions from 2 ng/mL to 0.2 pg/mL to simulate clinical
samples. The purified BoNT/B-spiked and BoNT-
negative sera were used as negative and blank samples
respectively. To determine the LOD of this strategy,
1 μL serum samples spiked with different concentrations
of BoNT/A and 1 μL substrate peptide solution were
added into 18 μL 0.01 M PBST containing 0.5 mM
ZnCl2 and incubated at 37 °C for the optimized diges-
tion duration. Afterwards, LFTSs were applied to those
samples by following the process previously mentioned
again. Meanwhile, MLA was used as the “gold standard
method” for methodological comparison.
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